NCT05683990View on ClinicalTrials.gov

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals At Risk for Type 1 Diabetes

PHASE2RecruitingINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Diabetes Mellitus, Type 1Autoimmune DiseasesPrevention

Interventions

DRUG

Diamyd

4 μg (0.1 mL) of Diamyd administered 1 month apart.

Trial Locations (1)

Unknown

RECRUITING

Lund University/CRC, Skåne University Hospital,, Malmo

Sponsors

Lead Sponsor

Diamyd Medical AB

All Listed Sponsors

lead

Diamyd Medical AB

INDUSTRY

NCT05683990 - Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals At Risk for Type 1 Diabetes | Biotech Hunter | Biotech Hunter